The study investigates the frequency and outcomes of coinfections in cancer patients who also have COVID-19, a group at high risk for such infections.
Among 8,765 patients analyzed, 16.6% developed coinfections, predominantly bacterial, with specific risk factors identified such as age, sex, and existing health conditions.
Co-occurrence of bacterial and fungal infections significantly increased the 30-day mortality rates, highlighting the severe impact of these coinfections in this vulnerable population.